Combining antivascular endothelial growth factor and anti-epidermal growth factor receptor antibodies: randomized phase II study of irinotecan and cetuximab with/without ramucirumab in second-line colorectal cancer (ECOG-ACRIN E7208). - Hochster HS; Catalano P; Weitz M; Mitchell EP; Cohen D; O'Dwyer PJ; Faller BA; Kortmansky JS; O'Hara MH; Kricher SM; Lacy J; Lenz HJ; et al. (Journal of the National Cancer Institute, 2024)